With the regulatory pathway cleared, the biosimilars market is poised to turn into a gold mine, growing up to 6,250% in 10 years. Here's where to stake your claim.
Achillion Pharmaceuticals has a big opportunity in hepatitis C, but it also faces some risks.
Motley Fool contributor Todd Campbell offers up two dividend-paying healthcare stocks to avoid and one that could be a good buy for long-term income investors.
Drug spending in the U.S. showed solid growth in several major indications; here’s what it means to you.
Acadia Pharmaceuticals' Parkinson's disease drug was guaranteed a speedy review and the attention of top FDA officials. So why did this company's stock recently tank so rapidly? There's a cautionary tale here for all biotech investors.
Gilead Sciences has been one of the fastest-growing biotech companies over the past few years. The company's rocket-like growth trajectory, though, is expected to start slowing starting this year. Should investors be concerned?
AbbVie Inc has agreed to pay $21 billion to acquire Pharmacyclics, Inc.
Pfizer Inc.'s acquisition of Hospira could signal that investors should embrace biosimilar drugmakers.
Three drug companies to watch as biologics come off patent and investors anticipate a biosimilar boom -- here's what you need to know.
Gilead Sciences has fallen by double-digits from its 52-week high. Is the stock now too cheap to ignore?